PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.29 Million USD | 9.54% |
| 2022 | 2.09 Million USD | -80.52% |
| 2021 | 10.75 Million USD | 87.02% |
| 2020 | 5.75 Million USD | 4567.15% |
| 2019 | 123.24 Thousand USD | 1767.11% |
| 2018 | 6601.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.7 Million USD | -25.8% |
| 2024 Q2 | 2.6 Million USD | 53.09% |
| 2023 Q3 | 3.77 Million USD | 30.97% |
| 2023 Q1 | 2.21 Million USD | 5.92% |
| 2023 FY | 2.29 Million USD | 9.54% |
| 2023 Q2 | 2.87 Million USD | 29.7% |
| 2023 Q4 | 2.29 Million USD | -39.12% |
| 2022 Q3 | 3.59 Million USD | -57.51% |
| 2022 Q4 | 2.09 Million USD | -41.65% |
| 2022 FY | 2.09 Million USD | -80.52% |
| 2022 Q1 | 8.6 Million USD | -20.01% |
| 2022 Q2 | 8.45 Million USD | -1.77% |
| 2021 Q3 | 18.42 Million USD | 0.0% |
| 2021 FY | 10.75 Million USD | 87.02% |
| 2021 Q4 | 10.75 Million USD | -41.62% |
| 2020 Q2 | 401.23 Thousand USD | 84.8% |
| 2020 Q1 | 217.11 Thousand USD | 0.0% |
| 2020 FY | 5.75 Million USD | 4567.15% |
| 2020 Q4 | 5.75 Million USD | 0.0% |
| 2019 FY | 123.24 Thousand USD | 1767.11% |
| 2018 FY | 6601.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 52.428% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | 3.395% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 94.103% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 98.269% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | 17.404% |
| Better Therapeutics, Inc. | 23.84 Million USD | 90.373% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 72.292% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 76.987% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 91.285% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 92.778% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 96.694% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 71.112% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 95.229% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 98.541% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 34.53% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 89.219% |
| Molecular Templates, Inc. | 31.17 Million USD | 92.636% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 81.659% |
| NexImmune, Inc. | 5.08 Million USD | 54.854% |
| Orgenesis Inc. | 35.53 Million USD | 93.541% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 86.099% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -761.566% |
| Scopus BioPharma Inc. | 7.45 Million USD | 69.209% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.536% |
| Statera Biopharma, Inc. | 22.67 Million USD | 89.878% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 78.969% |
| Trevena, Inc. | 48.26 Million USD | 95.244% |
| Vaxxinity, Inc. | 30.94 Million USD | 92.582% |
| Vaccinex, Inc. | 5.94 Million USD | 61.371% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -16.613% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 94.018% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | 16.883% |